α1-antitrypsin deficiency in lung and liver disease

Research output: Contribution to journalReview article

9 Scopus citations

Abstract

Prevention of lung disease is the major therapeutic imperative for patients with this genetic disorder. Definitive treatment involves replacement or augmentation of antielastase with human plasma-derived protease inhibitor in patients with early or mild chronic obstructive pulmonary disease. Measures to minimize the risk of serious hepatic involvement remain to be devised.

Original languageEnglish (US)
Pages (from-to)51-59
Number of pages9
JournalHospital Practice
Volume24
Issue number5
StatePublished - Jan 1 1989

ASJC Scopus subject areas

  • Medicine(all)

Fingerprint Dive into the research topics of 'α<sub>1</sub>-antitrypsin deficiency in lung and liver disease'. Together they form a unique fingerprint.

  • Cite this